Chronic Fatigue Syndrome
References
Aaron LA, Burke MM et al. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med . 2000 Jan 24;160(2):221–7.
Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry . 2003 Feb;160(2):221–36.
Anonymous. Mismatched double-stranded RNA: polyI:polyC12U. Drugs RD . 2004;5(5):297–4
Balch PA, Balch JF. Prescription for Nutritional Healing . 3rd ed. New York : Avery; 2000.
Behan PO, Behan WM, et al. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand . 1990 Sep;82(3):209–16.
Bentler SE, Hartz AJ, et al. Prospective observational study of treatments for unexplained chronic fatigue. J Clin Psychiatry . 2005 May;66(5):625–32.
Borish L, Schmaling K, et al. Chronic fatigue syndrome: identification of distinct subgroups on the basis of allergy and psychologic variables. J Allergy Clin Immunol . 1998 Aug;102(2):222–30.
Bou-Holaigah I, Rowe PC, et al. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA . 1995 Sep 27;274(12):961–7.
Bounous G, Molson J. Competition for glutathione precursors between the immune system and the skeletal muscle: pathogenesis of chronic fatigue syndrome. Med Hypotheses . 1999 Oct;53(4):347–9.
Bruno RL, Creange SJ, et al. Parallels between post-polio fatigue and chronic fatigue syndrome: a common pathophysiology? Am J Med . 1998 Sep 28;105(3A):66S–73S.
Calkins H, Rowe PC. Relationship between chronic fatigue syndrome and neurally mediated hypotension. Cardiol Rev . 1998 May;6(3):125–34.
Centers for Disease Control and Prevention (CDC). Available at: http://www.cdc.gov/ncidod/diseases/cfs/about/demographics.htm. Accessed November 2 , 2005a.
Centers for Disease Control and Prevention (CDC). Available at: http://www.cdc.gov/ncidod/diseases/cfs/. Accessed November 2 , 2005b.
Centers for Disease Control and Prevention (CDC). Available at: http://www.cdc.gov/ncidod/diseases/cfs/about/what.htm. Accessed November 2 , 2005c.
Chronic Fatigue and Immune Disorder Syndrome (CFIDS) Association of America . Available at: www.cfids.org/resources/newly-diagnosed-faq.asp. Accessed October 5, 2005.
Cleare AJ , Bearn J, et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord . 1995 Aug 18;34(4):283–9.
Cox IM, Campbell MJ, et al. Red blood cell magnesium and chronic fatigue syndrome. Lancet . 1991 Mar 30;337(8744):757–60.
De Becker P, De Meirleir K, et al. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. Horm Metab Res . 1999 Jan;31(1):18-21.
Demitrack MA. Chronic fatigue syndrome: a disease of the hypothalamic-pituitary-adrenal axis? Ann Med . 1994 Feb;26(1):1– 5.
Dimai HP, Porta S, et al. Daily oral magnesium supplementation suppresses bone turnover in young adult males. J Clin Endocrinol Metab . 1998 Aug;83(8):2742–8.
Droge W, Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J . 1997 Nov;11(13):1077–89.
Evengard B, Klimas N. Chronic fatigue syndrome: probable pathogenesis and possible treatments. Drugs . 2002;62(17):2433–46.
Forsyth LM, Preuss HG, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol . 1999 Feb;82(2):185–91.
Fulle S, Mecocci P, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med . 2000 Dec 15;29(12):1252–9.
Gerrity TR, Papanicolaou DA, et al. Immunologic aspects of chronic fatigue syndrome. Report on a research symposium convened by the CFIDS Association of America and co-sponsored by the US Centers for Disease Control and Prevention and the National Institutes of Health. Neuroimmunomodulation . 2004;11(6):351–7.
Gray JB, Martinovic AM. Eicosanoids and essential fatty acid modulation in chronic disease and the chronic fatigue syndrome. Med Hypotheses . 1994 Jul;43(1):31–42.
Grimble RF. Nutritional antioxidants and the modulation of inflammation: theory and practice. New Horiz . 1994;2(2):175–85.
Heap LC, Peters TJ, et al. Vitamin B status in patients with chronic fatigue syndrome. J R Soc Med . 1999 Apr;92(4):183–5.
Hendler SS, Rorvik D. PDR for Nutritional Supplements . 1st ed. Montvale , NJ : Thomson PDR; 2001.
Jacobson W, Saich T, et al. Serum folate and chronic fatigue syndrome. Neurology . 1993 Dec;43(12):2645–7.
Jamison JR. Clinical Guide to Nutrition and Dietary Supplements in Disease Management . Philadelphia , Pa : Churchill Livingstone; 2003: 790.
Jason LA, Corradi K, et al. Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev . 2005 Mar;15(1):29–58.
Judy W. Presentation to the 37th Annual Meeting of the American College of Nutrition. Southeastern Institute Research.1996.
Kasper DL, Braunwald E, et al. Harrison's Principles of Internal Medicine . 16th ed. New York : McGraw-Hill; 2005.
Kelly GS. L-carnitine: therapeutic applications of a conditionally-essential amino acid. Altern Med Rev . 1998 Oct;3(5):345–60.
Kingsbury KJ. Plasma amino acid patterns in elite athletes. Br J Sports Med . 1998a Sep;32(3):266–7.
Kingsbury KJ, Kay L, et al. Contrasting plasma free amino acid patterns in elite athletes: association with fatigue and infection. Br J Sports Med . 1998b Mar;32(1):25–32.
Kuratsune H, Yamaguti K, et al. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. Int J Mol Med . 1998 Jan;1(1):143–6.
Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev . 2001 Oct;6(5):450–9.
Patarca R. Cytokines and chronic fatigue syndrome. Ann N Y Acad Sci . 2001 Mar;933:185–200.
Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology . 1995;32(3):132–8.
Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology . 1997;35(1):16–23.
Richards RS, Roberts TK, et al. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep . 2000;5(1):35–41.
Scott LV , Dinan TG. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Funct Neurol . 1999a Jan;14(1):3–11.
Scott LV, Salahuddin F, et al. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. J Affect Disord . 1999b Jul;54(1–2):129–37.
Smirnova IV, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol Cell Biochem . 2003 Jun;248(1–2):93–5.
Stejskal VD, Danersund A, et al. Metal-specific lymphocytes: biomarkers of sensitivity in man. Neuroendocrinol Lett . 1999;20(5):289–98.
Streeten DH, Anderson GH, Jr. The role of delayed orthostatic hypotension in the pathogenesis of chronic fatigue. Clin Auton Res . 1998 Apr;8(2):119–24.
Tirelli U, Marotta G, et al. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol . 1994 Dec;40(6):601–8.
Tomoda A, Joudoi T, et al. Cytokine production and modulation: comparison of patients with chronic fatigue syndrome and normal controls. Psychiatry Res . 2005 Mar 30;134(1):101–4.
Ur E, White PD, et al. Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur Arch Psychiatry Clin Neurosci . 1992;241(5):317–22.
van Rensburg SJ, Potocnik FC, et al. Serum concentrations of some metals and steroids in patients with chronic fatigue syndrome with reference to neurological and cognitive abnormalities. Brain Res Bull . 2001 May 15;55(2):319–25.
Vecchiet J, Cipollone F, et al. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett . 2003 Jan 2;335(3):151–4.
Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med . 2004 Mar-Apr;66(2):276-82.
Vernon SD , Reeves WC. Evaluation of autoantibodies to common and neuronal cell antigens in chronic fatigue syndrome. J Autoimmune Dis . 2005 May 25;2(1):5.
Visser J, Blauw B, et al. CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. J Infect Dis . 1998 Feb;177(2):451–4.
Vollmer-Conna U, Lloyd A, et al. Chronic fatigue syndrome: an immunological perspective. Aust N Z J Psychiatry . 1998 Aug;32(4):523–7.
Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev . 2000 Apr;5(2):93–108.